

	Sunday 3 July		
13.00-17.30	Registration		
			Main auditorium
15.00	Welcome		Gunilla T. Westermark Uppsala, Sweden
	Chair persons Robert Kisilevsky/Angela Dispenzieri		
15.15-16.00	Opening lecture Amyloid and amyloidosis	O-1	Giampaolo Merlini Pavia, Italy
16.00-18.00	Basic science		
16.00-16.30	Keynote lecture Human protein atlas	O-2	Fredrik Pontén Uppsala, Sweden
16.30-16.45	Identifying germline genetic risk factors for immunoglobulin light chain amyloidosis	O-3	Miguel Inacio Da Silva Filho Heidelberg, Germany
16.45-17.00	The role of novel biomarkers in AL amyloidosis	O-4	Ga Yeon Lee Seoul, Korea
17.00-17.15	Immunotherapy against alpha-synuclein protofibrils as a therapeutic strategy for Parkinson's disease	O-5	Joakim Bergström Uppsala, Sweden
17.15-17.30	siRNA targeting the κ light chain constant region: A pre- clinical experimental approach to AL and non- fibrillar κ light chain deposition diseases	O-6	Xun Ma Boston, MA
17.30-17.45	Structural stability and local dynamics in disease-causing mutants of human apolipoprotein A-I: what makes the protein amyloidogenic?	O-7	Olga Gursky Boston, MA
17.45-18.15	Special lecture A backward glance at what gives us the future	O-8	Robert A. Kyle Rochester, MN
19.00	Welcome reception		Botanical garden
	Monday 4 July		Main auditorium
	Chair persons Marcus Fändrich/Jeffrey Kelly		
08.00	Basic science		
08.00-08.30	Keynote lecture		

	Chaperone in amyloidosis	O-9	Jan Johansson Stockholm, Sweden
08.30-09.00	Keynote lecture Amyloid and amyloids	O-10	David Eisenberg Los Angeles, CA
09.00-09.15	A bifunctional peptide, "peptope", for pre-targeting antibody 7D8 to systemic amyloid deposits.	O-11	Jonathan Wall Knoxville, TN
09.15-09.30	Acceleration of α -synuclein aggregation	O-12	Ricardo Gaspar Lund, Sweden
09.30-09.45	Carbamylation of the amino- terminal residue (Gly 1) of mouse SAA1.1 promotes amyloid fibril formation	O-13	Barbara Kluge-Beckerman Indianapolis, IN
09.45-10.15	Coffee break		
	Chair persons Jan Johansson/Maria Picken		
10.15-12.00	Basic science		
10.15-10.45	Keynote lecture Seeding and cross-seeding	O-14	Christopher M. Dobson Cambridge, UK
10.45-11.00	Co-fibrillogenesis of wild-type and D76N β 2-microglobulin: seeding effect or prion-like mechanism?	O-15	Vittorio Bellotti Pavia, Italy and London, UK
11.00-11.15	Molecular determinants of IAPP cross-amyloid interaction with A β	O-16	Aphrodite Kapurniotu Munich, Germany
11.15-11.30	Cross-seeding of medin and A-beta amyloid	O-17	Hannah Davies Liverpool, UK
11.30-12.00	Keynote lecture Treatment in pipeline	O-18	Sir Mark B. Pepys London, UK
12.00-13.30	Lunch and poster viewing		
	Chair persons Joel Buxbaum/Vaishali Santhorawala		
13.30-15.00	Imaging		
13.30-14.00	Keynote lecture <i>In vivo</i> detection of amyloid	O-19	Philip N. Hawkins London, UK
14.00-14.15	Regression of cardiac AL amyloidosis demonstrated by cardiovascular magnetic resonance: a new era of understanding	O-20	Ana Martinez Naharro London, UK
14.15-14.30	Visualisation of transthyretin heart amyloidosis by 11c-PIB and PET	O-21	Björn Pilebro Umeå, Sweden
14.30-14.45	Multicenter experience of planar technetium pyrophosphate cardiac	O-22	Adam Castano New York, NY

	imaging: Does preferential cardiac uptake predict survival in patients with ATTR cardiac amyloidosis?		
14.45-15.00	Cardiac amyloid imaging with ¹⁸ F-florbetaben positron emission tomography: a pilot study	O-23	Peter Mollee Queensland, Australia
15.00-15.30	Coffee break		
	Chair persons Gunilla Westermark/Ole Suhr		
15.30-17.00	Transthyretin		
15.30-16.00	Keynote lecture Transthyretin	O-24	Merrill D. Benson Indianapolis, IN
16.00-16.30	Keynote lecture Antibodies in TTR-amyloidosis	O-25	Yukio Ando Kumamoto, Japan
16.30-18.00	Poster presentations		
19.00-21.00	Satellite symposium Amylam		Main auditorium
	Tuesday 5 July		Main auditorium
08.00-10.00	Non-hereditary and hereditary ATTR amyloidosis		
08.00-09.30	Pathways for ATTR amyloid formation Presentations and discussion	O-26 O-27 O-28 O-29 O-30	Vittorio Bellotti, Pavia, Italy and London, UK David Eisenberg, Los Angeles, CA Jeffrey W. Kelly, La Jolla, CA (Chair) Ole B. Suhr, Umeå, Sweden Per Westermark, Uppsala, Sweden
	Chair persons Yukio Ando/Marcia W. Cruz		
9.30-09.45	Retinol Binding Protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis	O-31	Frederick Ruberg Boston, MA
09.45-10.00	Establishment of a diagnostic center for amyloidosis in Japan by Kumamoto University	O-32	Taro Yamashita Kumamoto, Japan
10.00-10.30	Coffee break		
10.30-10.45	Male gender is a risk factor for myocardial involvement in transthyretin-related amyloidosis: A study based on	O-33	Claudio Rapezzi Bologna, Italy

	the Transthyretin Amyloid Outcomes Survey		
10.45-11.00	Unveiling transthyretin cardiac amyloidosis as an etiology for paradoxical low-flow severe aortic stenosis in patients undergoing transcatheter aortic valve replacement	O-34	Adam Castano New York, NY
11.00-13.00	Satellite symposium Pfizer		Main auditorium
13.00-14.00	Lunch		
14.00-	AL amyloidosis		
	Chair persons Arnoud Jaccard/Ute Hegenbart		
14.00-14.30	Keynote lecture AL amyloidosis	O-35	Raymond L. Comenzo Boston, MA
14.30-14.45	Limited duration treatment with bortezomib and methylprednisone is effective in primary amyloidosis leading to results similar to those of high dose melphalan	O-36	Rafat Abonour Indianapolis, IN
14.45-15.00	Renal outcome among patients with systemic AL amyloidosis who present with advanced CKD is dependent on speed and magnitude of response to chemotherapy	O-37	Tamer Rezk London, UK
15.00-15.15	CS-1 chimeric antigen receptor adoptive t cell therapy for systemic light chain amyloidosis	O-38	Xiuli Wang Vuarde, CA
15.15-15.30	NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study	O-39	Morie A. Gertz Rochester, MN
15.30-17.30	Coffee		
15.30-17.30	Poster presentations		
17.30-20.30	Satellite symposium Prothena		Main auditorium

	Wednesday 6 July		Main auditorium
	More AL amyloidosis		
08.00-09.15	Debate Treatment of AL amyloidosis Stem cell transplantation or chemotherapy for front-line treatment of AL?	O-40 O-41 O-42 O-43	Morie A. Gertz, Rochester, MN Giampaolo Merlini, Pavia, Italy (Chair) Stephan Schönland, Heidelberg, Germany Martha Skinner, Boston, MA
09.15-11.00	AA amyloidosis		
	Chair persons Steven Zeldenrust/Lawreen Connors		
09.15-09.45	Keynote lecture Pathogenesis and status of AA amyloidosis	O-44	Bouke P.C. Hazenberg Groningen, the Netherlands
09.45-10.15	Coffee break		
10.15-10.30	AA amyloidosis related to familial mediterranean fever: a cohort study of 31 cases	O-45	Sophie Georgin-Lavialle Paris, France
10.30-10.45	Prognostication of survival and progression to dialysis in AA amyloidosis	O-46	Giovanni Palladini Pavia, Italy
10.45-11.00	Transcriptional upregulation and sequence variation in the SAA gene pathway in island foxes (<i>Urocyon littoralis</i>) with AA amyloidosis	O-47	Patricia Gaffney La Jolla, CA
11.00-12.30	Satellite symposium Bellus		Main auditorium
12.30-14.00	Lunch and Poster presentations		
	Chair persons Arie Stangou/Keiichi Higuchi		
14.00-15.05	More AA Other amyloid forms		
14.00-14.15	A clinical Phase 3 confirmatory trial of Kiacta™ in the treatment of AA amyloidosis	O-48	Giampaolo Merlini Pavia, Italy
14.15-14.30	Passive treatment with monoclonal antibodies to islet amyloid polypeptide significantly improved both haemoglobin A1c and glucose tolerance and decreased extracellular amyloid deposits	O-49	Wagner Zago San Francisco, CA

	in the transgenic HIP rat model of type 2 diabetes		
14.30-14.45	Prevalence of monoclonal gammopathy of unknown significance in ATTR-wild type patients	O-50	Hallie Geller Boston, MA
14.45-15.05	Apolipoprotein C-II amyloidosis	O-51 O-52	Laura Obici, Pavia, Italy Samih Nasr, Rochester, MN
15.05-15.30	Coffee break		
15.30-17.30	Parallel sessions: A. Liver and heart transplantation in amyloidosis B. Animal models		A. In Main auditorium B. In Hall B
15.30-17.30	A. Liver and heart transplantation in amyloidosis		Main auditorium
	Chair persons Bo-Göran Ericzon/Philip Hawkins		
15.30-16.00	Keynote lecture Liver transplantation	O-53	Bo-Göran Ericzon Stockholm, Sweden
16.00-16.30	Keynote lecture Heart transplantation	O-54	Mathew Maurer New York, NY
16.30-16.45	Transthyretin-type cerebral amyloid angiopathy in post-transplant patients with hereditary ATTR amyloidosis: Correlates between clinical findings and PIB-PET imaging	O-55	Yoshiki Sekijima Matsumoto, Japan
16.45-17.00	Evaluation of central nervous complications following liver transplantation in patients with hereditary transthyretin amyloidosis	O-56	Nicklas Wange Umeå, Sweden
17.00-17.15	Polyneuropathy after FAP domino liver transplantation	O-57	Göran Solders, Stockholm, Sweden
17.15-17.30	Cardiac dysautonomia predicts long term survival in hereditary transthyretin amyloidosis after liver transplantation	O-58	Michel Slama Paris, France
15.30-17.30	B. Animal models		Hall B

15.30-16.45	Presentations and discussion: Experimental animal models	O-59 O-60 O-61 O-62	Joel N. Buxbaum, La Jolla CA (Chair) Francesca Lavatelli, Pavia, Italy Maria J. Saraiva, Porto, Portugal Gunilla T. Westermark, Uppsala, Sweden
	Chair persons Jean D. Sipe/Joel Buxbaum		
16.45-17.00	Exploring the mechanism of cardiotoxicity in al amyloidosis: the C. elegans model	O-63	Paola Rognoni Pavia, Italy
17.00-17.15	Efficiency of siRNA for removal of transthyretin V30M in a TTR leptomeningeal animal model	O-64	Maria J. Saraiva Porto, Portugal
17.15-17.30	Serum amyloid A in the treatment of sepsis in a mouse model	O-65	Reinhold P. Linke Martinsreid, Germany
19.00	Dinner at Uppsala Castle		

	Thursday 7 July		
08.00-10.00	Parallel sessions General discussions		
08.00-09.15	Discussion I Suitable methodology for treatment evaluation	O-66 O-67 O-68	Main auditorium Teresa Coelho; Porto, Portugal Thibaud Damy, Paris, France Steven Zeldenrust, Rochester, MN (Chair)
	Chair persons Teresa Coelho/Raymond Comenzo		
09.15-09.30	The 6-minute walk test in AL amyloidosis patients: a single center experience	O-69	Vina Pulido Boston, MA
09.30-09.45	Lessons for future clinical trial design in cardiac amyloidosis - the experience of a prospective study in stage III cardiac AL amyloidosis (REVEAL study)	O-70	Ashutosh Wechalekar, London, UK
09.45-10.00	Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in a Stem Cell-Based in vitro Model	O-71	Christoph Niemietz Munster, Germany
10.00-10.15	Treatment of transthyretin cardiomyopathy with a TTR specific antisense oligonucleotide (IONIS-TTR Rx)	O-72	Merrill D. Benson Indianapolis, IN
08.00-09.15	Discussion II ThT assay pitfalls- can the method be standardised?	O-73 O-74 O-75 O-76	Hall B Jeffrey W. Kelly, La Jolla, CA Hironobu Naiki, Fukui, Japan Sofie Nyström, Linköping, Sweden Daniel Otzen, Aarhus, Denmark (Chair)
	Chair persons Daniel Otzen/Per Westermark		
09.15-09.30	FRET-based observation of intracellular SAA fibril formation	O-77	Stephanie Claus Ulm, Germany
09.30-09.45	First report of MYD88 L265P somatic mutation in IgM-associated light chain amyloidosis	O-78	Rajshekhar Chakraborty Rochester, MN
09.45-10.00	Cell damage in light chain amyloidosis: fibril internalization, toxicity and cell-mediated seeding	O-79	Marta Marin-Argany Knoxville, TN
10.00-10.15	Discovery of transthyretin stabilizers displaying resilience to the effect of the V30M mutation	O-80	Rui Brito Porto, Portugal
10.15-10.45	Coffee		

10.45-11.30	ISA members meeting: Report on the journal Amyloid (Per Westermark, editor). Election results. Future symposia.		Bouke P.C. Hazenberg/Angela Dispenzieri
11.30-12.00	Summary of the meeting		Main auditorium Martha Skinner Boston, MA
12.00	Closing remarks		Gunilla T. Westermark Ole B. Suhr Per Westermark
12.30-13.30	Grab & go lunch		